New analgesic lipopeptides to treat the irritable bowel syndrome

**DESCRIPTION**

The scientists characterized a family of compounds from the probiotic *Escherichia coli* strain Nissle 1979 with pain killer properties without toxicity.

The formula of the best compound is: C12-Asn-GABA. The lipidic part acts like a carrier, allowing the GABA to cross the intestinal and colorectal epithelial barrier and target the GABA$_B$ receptors of nerves.

These compounds inhibit neuronal activities and intestinal mecanical hypersensitivity.

**EXPERIMENTAL VALIDATIONS**

- C12-Asn-GABA crosses the epithelial barrier (shown *in-vitro* on human cells and *ex-vivo* and *in vivo* in mouse) contrary to GABA alone.
- C12-Asn-GABA inhibits sensory neuron activation via the GABA$_B$ receptors.
- C12-Asn-GABA does not impair duodenal activity (*ex-vivo* in mouse), it has no effect on inflammation, paracellular permeability nor intestinal motricity.
- C12-Asn-GABA does not cross the blood-brain barrier: the concentration of C12-Asn-GABA does not increase in the cortex and the hypothalamus after administration of C12-Asn-GABA.

**COMPETITIVE ADVANTAGES**

- Reduction of visceral pain
- No crossing of the blood-brain barrier
- Oral administration
- Optimizable family of compounds

**APPLICATIONS**

- Visceral pain and specifically in the irritable bowel syndrome

**INTELLECTUAL PROPERTY**

- European patent application N°17305481.8 filed in April 2017
- International extension in the US and in Europe

**DEVELOPMENT STAGE**

- Experimental proof of concept

**NEXT**

- Looking for an industrial partner to co-invest in the *in-vivo* proof-of-concept, the chemical optimization, PK/PD and toxicity studies

**LABORATORY**

**CONTACT**

T. +33 (0)5 62 25 50 60
sante@toulouse-tech-transfer.com
www.toulouse-tech-transfer.com

---

* Technology requiring license rights.
TTT_177. Non-contractual document. All rights reserved. May 2020.